Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tabirafusp alfa tedromer
- Development stage
- Unknown
- Lead developer
- Kodiak Sciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
Tabirafusp alfa tedromer (KSI-501) is an investigational bispecific antibody biopolymer conjugate (ABC) designed to simultaneously target and inhibit vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). Developed by Kodiak Sciences, the drug is built on their proprietary ABC platform, which conjugates a trap-antibody fusion protein to a high-molecular-weight phosphorylcholine-based biopolymer to enhance ocular half-life and durability. By combining anti-VEGF activity (to inhibit neovascularization and vascular permeability) with anti-IL-6 activity (to target underlying inflammation and immune-mediated resistance), tabirafusp alfa tedromer aims to provide superior efficacy and extended dosing intervals for retinal vascular diseases. It is currently in Phase 3 clinical development for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
- Other names
- tabirafusp-ted
02
Targets
IL-6 (Interleukin 6)IL-6R (Interleukin-6 receptor subunit alpha)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on tabirafusp alfa tedromer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tabirafusp alfa tedromer.